Changing Fortunes for CMOs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Changing Fortunes for CMOs
Contract manufacturers of APIs and intermediates are cautiously optimistic.


Pharmaceutical Technology
Volume 3, Issue 32


Patricia Van Arnum
The tide may be turning for contract manufacturing organizations (CMOs) of active pharmaceutical ingredients (APIs) and intermediates. In gauging opinion at Informex, the trade show of custom and batch manufactures, held in New Orleans Jan. 29–Feb. 1, 2008, many CMOs, armed with improved profitability and investment plans, were fairly upbeat following more subdued views from recent years.

Signs of optimism were apparent in the results of a business survey released at Informex by the Synthetic Organic Chemical Manufacturers Association (SOCMA). SOMCAis the US-based trade association of custom and batch manufacturers, and 92% of survey respondents characterized current business conditions as "excellent/very good" (54%) or "good" (38%). This outlook is better than in 2006, when only 82% rated business conditions as "excellent/very good" (53%) or "good" (29%).

In speaking with several CMOs, most concur with this sanguine view and see their growth largely being driven by emerging pharmaceutical companies. Their optimism, however, is tempered by the "R" word—recession—and the attendant macroeconomic factors that could affect the financing flow into these smaller companies. "Tighter lending practices and reduced private and equity investment could potentially hamper the liquidity of small bio and pharma companies, and this would be a concern for us," said one CMO.

As to Big Pharma, many CMOs say they have yet to see any uptick from recent manufacturing rationalization and intentions to increase outsourcing."Big Pharma has enough internal capacity. Whether companies will increase outsourcing remains to be seen," said one CMO.

Offer your opinions on this and other topics at http://blog.pharmtech.com/, our blog, which goes live later this month at Interphex.

Patricia Van Arnum is a senior editor with Pharmaceutical Technology,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here